ΨΥΧΟΛΟΓΙΑ - Έρευνα και Εφαρμογές ΤΕΥΧΟΣ 4ο | Page 66

ΙSSN: 2623- 3673
Φεβρουάριος, 2019
Ψυχολογία :έρευνα & εφαρμογές
14. Erzin G, Topcuoglu C, Kotan V, Bayram S, Fountoulakis K. Endocr Metab
Immune Disord Drug Targets. 2018 Feb 13; 18(2):163-169. Assessment of Irisin,
Adiponectin and Leptin Levels in Patients with Schizophrenia.
15. Bilgic S, Tastemir Korkmaz D, Azirak S, Guvenc AN, Kocaman N, Ozer
MK.Bratisl Lek Listy. 2017; 1 18(10):618-625. The protective effect of
thymoquinone over olanzapine-induced side effects in liver, and metabolic side
effects.
16.Chee G, Wynaden D, Heslop K. Arch Psychiatr Nurs. 2017 Dec; 31(6):624-
633. Improving metabolic monitoring rate for young people aged 35 and younger
taking antipsychotic medications to treat a psychosis: A literature review.
17. Frampton J. Drugs. 2017 Dec; 77(18):2049-2056. Aripiprazole Lauroxil: A
Review in Schizophrenia.
18. Jeon S, Kim Y. Int J Mol Sci. 2017 Oct 18; 18(10). Unresolved Issues for
Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic
Polypharmacy and Metabolic Syndrome.
19. Ragguett R, Hahn M, Messina G, Chieffi S, Monda M, De Luca V. Hum
Psychopharmacol. 2017 Nov; 32(6). Association between antipsychotic
treatment and leptin levels across multiple psychiatric populations: An updated
meta-analysis.
20. Handen B, Anagnostou E, Aman M, Sanders K, Chan J, Hollway J, Brian J,
Arnold L, Capano L, Williams C, Hellings J, Butter E, Mankad D, Tumuluru R,
Kettel J, Newsom C, Peleg N, Odrobina D, McAuliffe-Bellin S, Marler S, Wong
T, Wagner A, Hadjiyannakis S, Macklin E, Veenstra-VanderWeele J. J Am Acad
Child Adolesc Psychiatry. 2017 Oct; 56(10):849-856.e6. A Randomized,
Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced
by Antipsychotic Medication in Young People With Autism Spectrum Disorder:
Open-Label Extension.
21. Chandradasa M, Champika L, de Silva S, Kuruppuarachchi K. Trials. 2017
Sep 20;18(1):435. Topiramate's effectiveness on weight reduction in
overweight/obese persons with schizophrenia: study protocol for a randomized
controlled trial.
22. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de
Silva V. Neuropsychiatr Dis Treat. 2017 Aug 22;13:2231-2241. Antipsychotic-
associated weight gain: management strategies and impact on treatment
adherence.
23. Suetani R, Siskind D, Reichhold H, Kisely S.Psychopharmacology (Berl).
2017 Oct;234(20):2989-3008. Genetic variants impacting metabolic outcomes
among people on clozapine: a systematic review and meta-analysis.
24. Porfirio M, Gomes de Almeida J, Stornelli M, Giovinazzo S, Purper-Ouakil
D, Masi G.Neuropsychiatr Dis Treat. 2017 Aug 10;13:2167-2174. Can melatonin
prevent or improve metabolic side effects during antipsychotic treatments?
25. Mulcahy A, Normand S, Newcomer J, Colaiaco B, Donohue J, Lave J,
Keeler E, Sorbero M, Horvitz-Lennon M. Psychiatr Serv. 2017 Dec
1;68(12):1280-1287. Simulated Effects of Policies to Reduce Diabetes Risk
Among Adults With Schizophrenia Receiving Antipsychotics.